New drug combo tested for Hard-to-Treat brain tumors
NCT ID NCT06478212
Summary
This study is testing a new combination of two drugs, vorasidenib and temozolomide, for people with a specific genetic type of brain tumor called an IDH-mutant glioma. The first part of the study aims to find the safest and most effective dose. The second part will see how well this dose combination works at controlling the tumor and helping patients live longer. The trial is for adults and adolescents (12+) with this specific tumor type who have already had standard radiation therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, 100050, China
-
Christie Hospital
Manchester, M20 4BX, United Kingdom
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Erasmus MC
Rotterdam, 503015, Netherlands
-
H. Valle de Hebron
Barcelona, 08035, Spain
-
Hospital 12 de Octubre
Madrid, 28041, Spain
-
Huashan Hospital, Fudan University
Shanghai, 200040, China
-
Hôpital Pierre Wertheimer
Lyon, 69003, France
-
Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
IOV - Ospedale Busonera
Padua, 35128, Italy
-
IUCT-Oncopole Institut Universitaire du Cancer
Toulouse, 31059, France
-
Instituto Clinico Humanitas IRCCS
Rozzano, Milan, 20089, Italy
-
Kumamoto University Hospital
Kumamoto, 860-8556, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Vienna - AKH
Vienna, 01090, Austria
-
Medizinische Fakultät Mannheim, Universität Heidelberg
Mannheim, 68167, Germany
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nagoya University Hospital
Nagoya, 466-8550, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
Ospedale Molinette - Centro Oncologico Ematologico
Turin, 10126, Italy
-
The Royal Marsden in Sutton
Sutton, SM2 5PT, United Kingdom
-
The Tel Aviv Sourasky Medical Center (TASMC) (Ichilov Hospital)
Tel Aviv, 64239, Israel
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
Conditions
Explore the condition pages connected to this study.